Please assess the completion status of the following clinical trial:

Trial Title: A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients 12 years of age and older.~* Confirmed diagnosis of HAE type I or II at any time in the medical history.~* Patient has access to and ability to use conventional on-demand treatment for HAE attacks.~* If a patient is receiving long-term prophylactic treatment with one of the protocol-allowed therapies, they must be on a stable dose and regimen for at least 3 months prior to the Screening Visit (except for danazol, which requires a stable dose and regimen for 6 months prior to the Screening Visit). Patient must be willing to remain on a stable dose and regimen for the duration of the trial.~* Patient's last dose of attenuated androgens other than danazol was at least 28 days prior to randomization.~* Patient:~  1. has had at least 2 documented HAE attacks within 3 months prior to screening or randomization; or~ 2. is a completer of the KVD824-201 trial within 3 months prior to randomization and meets all other entry criteria to enroll in KVD900-301~* Patients must meet the contraception requirements.~* Patients must be able to swallow trial tablets whole.~* Patients, as assessed by the Investigator, must be able to appropriately receive and store IMP, and be able to read, understand, and complete the electronic diary (eDiary).~* Investigator believes that the patient is willing and able to adhere to all protocol requirements.~* Patient provides signed informed consent or assent (when applicable). A parent or legally authorized representative (LAR) must also provide signed informed consent when required.~Exclusion Criteria:~* Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1-inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.~* A clinically significant history of poor response to bradykinin receptor 2 (BR2) blocker, C1-INH therapy or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator.~* Use of angiotensin-converting enzyme (ACE) inhibitors after the Screening Visit or within 7 days prior to randomization.~* Any estrogen containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Screening Visit.~* Patients who require sustained use of strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers.~* Inadequate organ function, including but not limited to:~  1. Alanine aminotransferase (ALT) \>2x upper limit of normal (ULN)~ 2. Aspartate aminotransferase (AST) \>2x ULN~ 3. Bilirubin direct \>1.25x ULN~ 4. International normalized ratio (INR) \>1.2~ 5. Clinically significant hepatic impairment defined as a Child-Pugh B or C~* Any clinically significant comorbidity or systemic dysfunction, which in the opinion of the Investigator, would jeopardize the safety of the patient by participating in the trial.~* History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.~* Known hypersensitivity to KVD900 or placebo or to any of the excipients.~* Prior participation in trial KVD900-201.~* Participation in any gene therapy treatment or trial for HAE.~* Participation in any interventional investigational clinical trial (with the exception of KVD824-201), including an investigational COVID-19 vaccine trial, within 4 weeks of the last dosing of investigational drug prior to screening.~* Any pregnant or breastfeeding patient.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- KVD900 600 mg (Type: EXPERIMENTAL): None
- KVD900 300 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete